Researchers and Executives from almost 50 clinical trial sites, pharmaceutical companies and technology partners to collaborate on improving research & treatment options
Las Vegas., Feb. 20, 2026- From February 25 through February 27 the Global Alzheimer’s Platform Foundation® (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s and neurodegenerative clinical trials in pursuit of a cure, will convene nearly 250 representatives from its network of 100+ clinical research sites, GAP-Net, in Las Vegas at the Red Rock Casino Resort and Spa.
The conference is an unparalleled gathering uniquely dedicated to improving clinical trials by bringing together clinical research leadership and executive teams from leading Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trial sites across North America, pharmaceutical sponsors, Contract Research Organizations (CRO), and other partners and industry leaders committed to accelerating clinical research.
WHEN:?February 25 – February 27
WHERE: Red Rock Casino Resort and Spa
WHO: World class researchers, experts, industry partners, and business leaders from GAP-Net’s 100+ clinical trial sites across the United States and Canada, and more, including representatives from Abbvie, Axiom Brain Health, Anavex, Banner Health, Beckman Coulter, Biogen, Brainscope, Catalyst Charter Research, Cogstate, Cumulus Neuro, Eisai, Eli Lilly and Co, Evolution Research Group (ERG), Fujirebio, GE Healthcare, IQVIA, IXICO,Linus Health, K2 Medical Research, Positrigo, Quanterix, Roche, Siemens Healthineers, SiteRX, SpearBio, and UNLV will also be in attendance. GAP President John Dwyer will speak to the research progress made by all as GAP celebrates its first decade as an organization working to accelerate the progress of neurodegenerative research, and what is coming next.
WHAT: The conference will fuel innovation through its unique collaboration, encouraging strong relationships to form while holding discussions around the future of Alzheimer’s disease research, navigating the changing landscape in the country, and the use of blood-based biomarkers.
The GAP 2025 National Citizen Scientist Awards® will also be presented, as six clinical trial participants, study partners, and community partners will be recognized for their time, passion, and dedication to helping find treatments and an eventual cure for Alzheimer’s and Parkinson’s diseases through their volunteerism.
The backdrop of the conference changes each year to reflect the capabilities of the network, its reach across the country, and the local impact that Alzheimer’s disease carries. In Nevada, it is estimated that nearly 55,000 people are currently living with Alzheimer’s disease, and experts predict that this number will dramatically increase. In recognizing the need for more clinical research in the state, the setting is fitting the mission for finding a cure.
To learn more, GAP can arrange interviews with leading researchers from across the U.S. and Canada, as well as with GAP President John Dwyer and GAP leaders. They can speak to the latest breakthroughs in clinical research for Alzheimer’s disease and Parkinson’s disease, the challenges facing Alzheimer’s clinical trials, and strategies to overcome them to find a cure.
For more information on GAP, visit?https://globalalzplatform.org/.
—END—
About GAP
The?Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).